Banner Life Sciences Patent-Cliff Exposure & CMS Drug Spending Portfolio

Banner Life Sciences (US): 1 reconciled FDA prescription therapies, $11.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2035-01-01
2024 CMS Total Public Spend$11.5M
2024 Medicare Part D Spend$8.2M
2024 Medicaid Spend$3.2M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel